Antithrombotics and Anticoagulants in Coronary Syndromes and Stroke

Alexander G. G. Turpie

doi:10.1055/s-2000-9245

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2000; Volume 26(Number s1): 085-086
DOI: 10.1055/s-2000-9245

Antithrombotics and Anticoagulants in Coronary Syndromes and Stroke

Alexander G.G. Turpie

Hamilton Health Sciences Corporation, General Division, Hamilton, Ontario, Canada

Abstract

ABSTRACT

The low-molecular-weight heparins (LMWHs) have been proven superior to placebo in reducing the incidence of acute coronary ischemic syndromes. Comparative studies vs. unfractionated heparin have not demonstrated superiority in favor of the LMWH dalteparin. In the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events (ESSENCE) trial, enoxaparin was demonstrated to have a benefit over heparin. The results have contributed to a better understanding of the relative efficacy of LMWHs in acute coronary syndromes. A second trial with enoxaparin supported the conclusions of the ESSENCE trial.

The antithrombotic effects of LMWHs have also been evaluated for the management of ischemic stroke with varied results. A trial assessing tinzaparin in acute ischemic stroke has completed enrollment, and its results may shed new light on the use of an LMWH for the management of stroke.

KEYWORD

Low-molecular-weight heparin - acute ischemic syndrome - stroke

Full Text

References

REFERENCES

1 Yeghiazarians Y, Braunstein J B, Askari A, Stone P H. Medical progress: Unstable angina pectoris. N Engl J Med . 2000; 342 101-114
2 Opinions regarding the diagnosis and management of venous thromboembolic disease. ACCP Consensus Committee on Pulmonary Embolism. Chest. 1998; 113 499-504
3 Collaborative overview of randomised trials of antiplatelet therapy-I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. Br Med J. 1994; 308 81-106
4 Turpie A G. Anticoagulants in acute coronary syndromes. Am J Cardiol . 1999; 84 2M-6M
5 Balsano F, Rizzon P, Violi F. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group. Circulation . 1990; 82 17-26
6 CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet . 1996; 348 1329-1339
7 Théroux P, Waters D, Qiu S. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation . 1993; 88(5 pt 1) 2045-2048
8 Turpie A G. Clinical potential of antithrombotic drugs in coronary syndromes. Am J Cardiol . 1998; 82 11L-14L
9 Théroux P, Ouimet H, McCans J. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med . 1988; 319 1105-1111
10 The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet . 1990; 336 827-830
11 Cohen M, Adams P C, Parry G. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Circulation . 1994; 89 81-88
12 Gurfinkel E, Fareed J, Antman E, Cohen M, Mautner B. Rationale for the management of coronary syndromes with low-molecular-weight heparins. Am J Cardiol . 1998; 82 15L-18L
13 FRagmin during Instability in Coronary Artery Disease (FRISC) study group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet . 1996; 347 561-568
14 Wallentin L, Husted S, Kontny F, Swahn E. Long-term low-molecular-weight heparin (Fragmin) and/or early revascularization during instability in coronary artery disease (the FRISC II Study). Am J Cardiol . 1997; 80 61E-63E
15 Klein W, Buchwald A, Hillis S E. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study. Circulation . 1997; 96 61-68
16 Cohen M, Demers C, Gurfinkel E P. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med . 1997; 337 447-452
17 Goodman S, Bigonzi F, Radley D, LeIouer V, Gosset F, Cohen M. One-year follow-up of the ESSENCE trial (enoxaparin versus heparin in unstable angina and non-Q-wave myocardial infarction). Eur Heart J. 1998; 50 (50 (Abstr))
18 The FRAX.I.S. Study Group.. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome). Eur Heart J . 1999; 20 1553-1562
19 FRagmin and Fast Revascularization during InStability in Coronary artery disease (FRISC II) Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet . 1999; 354 708-715
20 Antman E M, McCabe C H, Gurfinkel E P. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation . 1999; 100 1593-1601
21 International Stroke Trial Collaborative Group. The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet . 1997; 349 1569-1581
22 CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet . 1997; 349 1641-1649
23 Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. JAMA. 1998; 279 1265-1272
24 Kay R, Wong K S, Yu Y L. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med . 1995; 333 1588-1593
25 Hommel M, FISS bis Investigators Group. Fraxiparine in Ischaemic Stroke Study (FISS bis). Cerebrovasc Dis. 1998; 8 ((Suppl 4) (Abstr)) 1-103